Identification of a novel series of potent RON receptor tyrosine kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 9, 2010, Pages 2745-2749

  Raeppel, Stéphane ^a   Gaudette, Frédéric ^a   Mannion, Michael ^a   Claridge, Stephen ^a   Saavedra, Oscar ^a   Isakovic, Ljubomir ^a   Déziel, Robert ^a   Beaulieu, Normand ^a   Beaulieu, Carole ^a   Dupont, Isabelle ^a   Nguyen, Hannah ^a   Wang, James ^a   Macleod, A Robert ^a   Maroun, Christiane ^a   Besterman, Jeffrey M ^a   Vaisburg, Arkadii ^a  

^a METHYLGENE INC   (Canada)

Author keywords

c Met; Oncology; RON; RTK inhibitors; Thieno 3,2 b pyridine

Indexed keywords

1 PHENYL 5 (TRIFLUOROMETHYL) 1H PYRAZOLE 4 CARBOXAMIDE; AMIDE; N[3 FLUORO 4 (2 THIENO[3,2 B]PYRIDIN 7 YLOXY)PHENYL] 1 PHENYL 5 (TRIFLUOROMETHYL) 1H PYRAZOLE 4 CARBOXAMIDE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950858132     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.03.073     Document Type: Article

References (35)

1. Blume-Jensen P., and Hunter T. Nature 411 (2001) 355
2. For recent reviews see:. Danilkovitch-Miagkova A. Curr. Cancer Drug Targets 3 (2003) 31
3. Wang M.-H., Wang D., and Chen Y.-Q. Carcinogenesis 23 (2003) 1291
4. Camp E.R., Liu W., Fan F., Yang A., Somcio R., and Ellis L.M. Ann. Surg. Oncol. 12 (2005) 273
5. Wang M.-H., Yao H.-P., and Zhou Y.-Q. Acta Pharmacol. Sin. 27 (2006) 641
6. Leonis M.A., Thobe M.N., and Waltz S.E. Future Oncol. 3 (2007) 441
7. Lu Y., Yao H.-P., and Wang M.-H. Cancer Lett. 257 (2007) 157
8. Wagh P.K., Peace B.E., and Waltz S.E. Adv. Cancer Res. 100 (2008) 1
9. Cheng H.-L., Liu H.-S., Lin Y.-J., Chen H.H.-W., Hsu P.-Y., Chang T.-Y., Ho C.-L., Tzai T.-S., and Chow N.-H. Br. J. Cancer 92 (2005) 1906
10. O'Toole J.M., Rabenau K.E., Burns K., Lu D., Mangalampalli V., Balderes P., Covino N., Bassi R., Prewett M., Gottfredsen K.J., Thobe M.N., Cheng Y., Li Y., Hicklin D.J., Zhu Z., Waltz S.E., Hayman M.J., Ludwig D.L., and Pereira D.S. Cancer Res. 66 (2006) 9162
11. Camp E.R., Yang A., Gray M.J., Fan F., Hamilton S.R., Evans D.B., Hooper A.T., Pereira D.S., Hicklin D.J., and Ellis L.M. Cancer 109 (2007) 1030
12. Beaulieu, N. et al. (poster session). 18th Symposium of EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics', Praha, Czech Republic, 7-10 November 2006. EJC Suppl. 4(12):35. (Abstract #410).
13. For recent reviews see:. Ma P.C., Maulik G., Christensen J., and Salgia R. Cancer Metastasis Rev. 22 (2003) 309
14. Birchmeier C.W., Birchmeier W., Gherardi E., and Vande Woude G.F. Nat. Rev. Mol. Cell Biol. 4 (2003) 915
15. Christensen J.G., Burrows J., and Salgia R. Cancer Lett. 225 (2005) 1
16. Corso S., Comoglio P.M., and Giordano S. Trends Mol. Med. 11 (2005) 284
17. Boccaccio C., and Comoglio P.M. Nat. Rev. Cancer 6 (2006) 637
18. Peruzzi B., and Bottaro D.P. Clin. Cancer Res. 12 (2006) 3657
19. Knudsen B.S., and Vande Woude G. Cur. Opin. Gen. Dev. 18 (2008) 87
20. Toschi L., and Jänne P.A. Clin. Cancer Res. 14 (2008) 5941
21. Dussault I., and Bellon S.F. Anti-Cancer Agents Med. Chem. 9 (2009) 221
22. Cipriani N.A., Abidoye O.O., Vokes E., and Salgia R. Lung Cancer 63 (2009) 169
23. Porter J. Expert Opin. Ther. Patents 20 (2010) 159
24. Underiner T.L., Herbertz T., and Miknyoczki S.J. Anti-Cancer Agents Med. Chem. 10 (2010) 7
25. Zhang Y., Kaplan-Lefko P.J., Rex K., Yang Y., Moriguchi J., Osgood T., Mattson B., Coxon A., Reese M., Kim T.-S., Lin J., Chen A., Burgess T.L., and Dussault I. Cancer Res. 68 (2008) 6680
26. Liu L., Siegmund A., Xi N., Kaplan-Lefko P., Rex K., Chen A., Lin J., Moriguchi J., Berry L., Huang L., Teffera Y., Yang Y., Zhang Y., Bellon S.F., Lee M., Shimanovich R., Bak A., Dominguez C., Norman M.H., Harmange J.-C., Dussault I., and Kim T.-S. J. Med. Chem. 51 (2008) 3688
27. Schroeder G.M., An Y., Cai Z.-W., Chen X.-T., Clark C., Cornelius L.A.M., Dai J., Gullo-Brown J., Gupta A., Henley B., Hunt J.T., Jeyaseelan R., Kamath A., Kim K., Lippy J., Lombardo L.J., Manne V., Oppenheimer S., Sack J., Schmidt R.J., Shen G., Stefanski K., Tokarski J.S., Trainor G.L., Wautlet B.S., Wei D., Williams D.K., Zhang Y., Zhang Y., Fargnoli J., and Borzilleri R. J. Med. Chem. 52 (2009) 1251
28. Raeppel S., Claridge S., Saavedra O., Gaudette F., Zhan L., Mannion M., Zhou N., Raeppel F., Granger M.-C., Isakovic L., Déziel R., Nguyen H., Beaulieu N., Beaulieu C., Dupont I., Robert M.-F., Lefebvre S., Dubay M., Rahil J., Wang J., Ste-Croix H., Macleod A.R., Besterman J., and Vaisburg A. Bioorg. Med. Chem. Lett. 19 (2009) 1323
29. Gaudette F., Raeppel S., Nguyen H., Beaulieu N., Beaulieu C., Dupont I., Macleod A.R., Besterman J., and Vaisburg A. Bioorg. Med. Chem. Lett. 20 (2010) 848
30. 50 curves using a 4-parameter fit model. These curves were calculated using GraFit 5.0 software. TPR-RON was first described by Santoro, M. M.; Collesi, C.; Grisendi, S.; Gaudino, G.; Comoglio, P. M. Mol. Cell Bio. 1996, 16, 7072.
31. 50s were calculated in a 4 parameters equation curve plotting inhibition (%).
32. The details for the synthesis and the characterization of all the new compounds are described in WO 2007/107005 A1, US 2008/0004273 A1 and WO 2008/046216.
33. Thobe M.N., Gurusamy D., Pathrose P., and Waltz S.E. Oncogene 29 (2010) 214
34. To confirm the cell based efficacy of the lead compound on endogenous RON, PC-3 cancer cells or HCT116 cancer cells were treated for 3 h with the indicated doses of compounds. Endogenously expressed RON proteins were immunoprecipitated from cell lysates with anti-RON-beta total (c-20) (Santa cruz biotechnologies) and subjected to immunoblotting analysis using anti-phospho-tyrosine (Millipore, 4G10) or anti-RON-beta total (c-20) (Santa cruz biotechnologies) as indicated. Protein detection was completed using anti-mouse or anti-rabbit horseradish peroxidase (trueblot from e-Bioscience), and subsequently incubated with chemiluminescent substrate solution (ECL plus, Roche). Fluorescent signal was captured on a Storm apparatus (Amersham Biosciences).
35. Chen Y.-Q., Zhou Y.-Q., Angeloni D., Kurtz A.L., Qiang X.-Z., and Wang M.-H. Exp. Cell Res. 261 (2000) 229